IRF2BP2 and metabolic dysfunction-associated steatotic liver disease: Furthermore, four (OSGIN1, AHR, IRF2BP2, and RASGEF1B) were shown to be strongly regulated upon LGZG therapy, which may play potential roles in NAFLD physiopathology (Figure 7, Table 1).